BioAlliance To Regain Full US Rights For Oravig


BioAlliance Pharma has decided to regain full US commercialisation rights for Oravig (a miconazole mucoadhesive tablet for the treatment of oropharyngeal candidiasis), as well as the NDA. After one year of marketing by American partner Vestiq Pharmaceutical, the sales performance of Oravig was not meeting expectations. BioAlliance is already in advanced discussions with potential partners for the acquisition or for a licensing agreement of the product.

BioAlliance also provided details on Loramyc (the tradename for Oravig outside of the US)'s development in Japan. In Japan, as usually required by Japanese authorities, a complementary development plan is driven by Sosei to complete the registration file. After a first successful Phase I trial, the pivotal Phase III trial, initiated in March 2013, should be completed by the end of 2014. Upon Loramyc registration, BioAlliance should receive a significant milestone payment from Sosei. Moreover, Sosei has implemented a commercialisation agreement with Fujifilm Pharma for the promotion and distribution of Loramyc in Japan once its marketing authorisation is obtained.

Pharma Agreements Database
Companies Involved BioAlliance Pharma, Vestiq Pharmaceutical
Date Announced 01/04/2014
Agreement Status Terminated
Date Last Reported 24/09/2012
Duration
Agreement Type Commercialisation
Estimated Total Value US$44mn
Therapeutic Area General Anti-infectives Systemic
Technology/Field N/A
Related Agreement BioAlliance/Vestiq enter commercialisation agreement for Oravig in US
Source: Espicom
This article is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: United States, France, Japan